Mankind Pharma has completed the divestment of its 100% stake in Broadway Hospitality Services Private Limited, finalizing the transaction on July 27, 2026. The pharmaceutical company secured a cash consideration of ₹49 crore for the sale, subject to closing adjustments. This move marks the conclusion of the strategic exit from its hospitality subsidiary, allowing management to focus on core pharmaceutical operations. The deal was executed through a Share Purchase Agreement signed on the same day.

The company disclosed the completion of the transaction to BSE Limited and the National Stock Exchange of India Limited. The intimation was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This filing serves as a final update following an earlier communication dated July 11, 2026, which contained the detailed disclosures required by the regulations.

Transaction Details

The key terms of the completed transaction are outlined below:

The consideration amount is subject to closing adjustments, as per the terms agreed upon in the Share Purchase Agreement. No further financial details regarding the working capital or net asset value adjustments were provided in this specific update.

Regulatory Compliance

The disclosure aligns with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. Mankind Pharma stated that the detailed disclosure required under this circular had already been submitted in its earlier communication on July 11, 2026. Therefore, this latest filing primarily confirms the execution of the agreement and the transfer of ownership.

Hitesh Kumar Jain, Company Secretary & Compliance Officer of Mankind Pharma Limited, signed the disclosure. The digital signature was timestamped on July 27, 2026, at 17:12:50 +05'30'. The company requested stock exchanges to take the information on record, marking the formal closure of the divestment process.

Mankind Pharma witnessed a notable block trade on the National Stock Exchange (NSE), with approximately 76,445 shares changing hands in a single transaction. The deal was executed at a price of ₹2559.90 per share, aggregating to a total transaction value of ₹19.57 crores.

Block Trade Details

The following table summarises the key parameters of the block trade recorded on the NSE:

Block trades are large, privately negotiated transactions that are executed outside the open market order book. Such trades are typically carried out by institutional investors and are reported separately on the exchange platform. The execution of this trade at ₹2559.90 per share on the NSE marks a significant single-transaction event for Mankind Pharma's stock.